Gilead's Next HIV Triple-Combo Pill May Prevent Generic Erosion; Can It Prevent Infection Itself?
This article was originally published in The Pink Sheet Daily
Executive Summary
The company filed for FDA approval of a combination of Truvada with J&J's investigational non-nucleoside reverse transcriptase inhibitor TMC278, a regimen that could supplant Atripla.